BACKGROUND:Once-daily long-acting β2-agonists (LABAs) are an important treatment option, either alone or in combination with other inhaled long-acting bronchodilators in the management of chronic obstructive pulmonary disease (COPD). AIMS/OBJECTIVES:To audit the effectiveness of indacaterol as maintenance therapy in patients with moderate-to-severe COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] stage II/III). METHODS:This was a single-center audit of a primary care COPD cohort comprising all patients treated with indacaterol following treatment escalation (as per National Institute for Health and Care Excellence guidelines) or failure with other therapies. The sample was restricted to patients treated for a minimum of 12 months with indacaterol, for whom preswitching and follow-up spirometry as well as exacerbation frequency data were available (GOLD spirometry guidelines). Pulmonary function was assessed by spirometry (recorded as forced expiratory volume in 1 second [FEV1] expressed as percentage predicted). Relevant self-reported qualitative information was recorded in descriptive terms for quality of life (QoL) assessment. RESULTS:A total of 15 patients met the audit inclusion criteria (66.6% male, mean age 64.9±7.7 years). COPD disease duration ranged from 1 to 22 years; 93% had GOLD stage II or III COPD. Follow-up ranged in duration from 12 to 27 months. Indacaterol was associated with a significant reduction in exacerbation frequency compared with the 12 months prior to initiation (P=0.02). In those patients who experienced three or more exacerbations/year, mean exacerbation rate fell from 5.43±1.07 to 2.43±0.2 after 12 months treatment with indacaterol (P=0.02). A reduction in dyspnea was noted in 53% of patients. Similarly, improvements in exercise tolerance and well-being were self-reported in 67% and 93%, respectively. CONCLUSION:Indacaterol was found to be an effective LABA as an escalation or switch medication in patients with moderate-to-severe COPD. Indacaterol was effective both as monotherapy and in combination with a long-acting muscarinic antagonist. Switching to indacaterol from a LABA/inhaled corticosteroid fixed-combination inhaler significantly reduced the number of acute exacerbations and also improved self-reported QoL.

译文

背景:每天一次的长效β2-激动剂(LABAs)在治疗慢性阻塞性肺疾病(COPD)时,单独或与其他吸入的长效支气管扩张剂联合使用,是一种重要的治疗选择。
目的/目的:评估茚达特罗在中重度COPD患者(慢性阻塞性肺病[GOLD] II / III期全球倡议)中作为维持治疗的有效性。
方法:这是一次初级保健COPD队列的单中心审核,包括所有在治疗升级(根据美国国立卫生与医疗保健研究院指南)后使用茚达特罗治疗的患者或其他治疗失败的患者。该样品仅限于使用茚达特罗治疗至少12个月的患者,他们可获得转换前和随访肺活量测定以及病情加重频率数据(GOLD肺活量测定指南)。通过肺活量测定法评估肺功能(记录为1秒内的呼气量[FEV1],以预测百分比表示)。有关自我报告的定性信息以描述性的方式记录下来,以进行生活质量(QoL)评估。
结果:共有15例患者符合审核纳入标准(男性66.6%,平均年龄64.9±7.7岁)。慢性阻塞性肺病的病程为1至22年。 93%的患者患有GOLD II或III期COPD。随访时间为12至27个月。与开始前的12个月相比,茚达特罗使发作频率显着降低(P = 0.02)。在那些每年发作三次或以上的患者中,用茚达特罗治疗12个月后,平均发作率从5.43±1.07降至2.43±0.2(P = 0.02)。观察到53%的患者呼吸困难减少。同样,自我报告的运动耐力和幸福感改善分别为67%和93%。
结论:对于中重度COPD患者,茚达特罗被认为是一种有效的LABA,可作为逐步升级或转换用药。茚达特罗作为单一疗法和与长效毒蕈碱拮抗剂联合均有效。从LABA /吸入皮质类固醇固定组合吸入器改用茚达特罗可显着减少急性加重次数,并改善自我报告的QoL。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录